NVCN - Neovasc Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.8010
-0.0990 (-2.54%)
As of 3:22PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close3.9000
Open3.9100
Bid3.8000 x 3000
Ask3.8500 x 1000
Day's Range3.7400 - 3.9300
52 Week Range3.7000 - 45.8000
Volume88,789
Avg. Volume325,532
Market Cap28.536M
Beta (3Y Monthly)2.21
PE Ratio (TTM)N/A
EPS (TTM)-25.4860
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.88
Trade prices are not sourced from all markets
  • PR Newswireyesterday

    Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule, Resolving Last Remaining Outstanding Nasdaq Deficiency

    VANCOUVER, July 17, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that it has received written notification (the "Nasdaq Notice") from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has regained compliance with the minimum bid price requirement set forth in the rules for continued listing on the Nasdaq Capital Market (the "Listing Rules"). Having regained compliance in respect of the minimum bid price deficiency and, as previously announced on June 25, 2019, the market value of listed securities deficiency, Neovasc has regained compliance in respect of all deficiency notices received from Nasdaq.

  • PR Newswire2 days ago

    Neovasc Provides Further Update on Reducer™ Program for Treatment of Refractory Angina

    Pending U.S. Food and Drug Administration ("FDA") Humanitarian Use Device ("HUD") Classification and Approval as a HUD, Company Expects to Begin Commercializing Reducer in U.S. by Early ...

  • CNW Group3 days ago

    Neovasc Participates in Round-Robin Study Evaluating In-Vitro Pulsatile Flow Testing of Prosthetic Heart Valves

    Hydrodynamic performance testing is one of the core in vitro assessments required by the ISO 5840 series of standards for all prosthetic heart valves. A round-robin study carried out in 2005 in accordance with ISO 5840:2005 revealed significant variabilities in prosthetic heart valve hydrodynamic performance measurements among the participating laboratories.

  • PR Newswire6 days ago

    Neovasc to Explore HDE Approval Pathway and Alternate Trial Designs for the Reducer Following Guidance from the FDA

    VANCOUVER, July 12, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the Food and Drug Administration ("FDA") has provided guidance to the Company following its Sprint Discussion on June 26, 2019, together with the Company's consultants and supporting U.S. cardiologists to review the clinical evidence collected to date for the Neovasc Reducer™ (the "Reducer"), to determine the most expedient pathway to potentially gaining regulatory approval in the United States and the quickest path to the U.S. market for these patients with an unmet need. In its guidance, the FDA has recommended that the Company consider potential alternate approaches such as: the Humanitarian Device Exemption ("HDE") pathway for class IV refractory angina patients and/or alternate clinical trial designs for a broader refractory angina patient population.

  • CNW Group20 days ago

    Neovasc Announces Effective Date of Share Consolidation

    VANCOUVER , June 28, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that the Company has filed articles of amendment, effective today, to effect the previously announced share consolidation (reverse stock split) (the "Consolidation") of its issued and outstanding common shares (the "Common Shares") on the basis of one (1) post-Consolidation Common Share for every ten (10) pre-Consolidation Common Shares. The Consolidation will reduce the number of Common Shares issued and outstanding from approximately 74,811,888 Common Shares to approximately 7,481,157 Common Shares.

  • PR Newswire21 days ago

    Neovasc Announces Presentations on Tiara™ for Treatment of Mitral Regurgitation and Reducer™ for Treatment of Refractory Angina at the CSI Frankfurt 2019 Conference

    VANCOUVER, June 27, 2019 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that its Tiara™ ("Tiara") transcatheter mitral valve replacement device and its Neovasc Reducer™ ("Reducer") device for the treatment of refractory angina were highlighted in presentations at the CSI Frankfurt 2019 conference, being held June 26-29, 2019, at the Congress Center Frankfurt, in Frankfurt, Germany.

  • CNW Group23 days ago

    Neovasc Regains Compliance with Nasdaq Minimum Market Value Rule

    VANCOUVER , June 25, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that it has received written notification (the "Nasdaq Notice") from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has regained compliance with the minimum market value requirement set forth in the rules for continued listing on the Nasdaq Capital Market (the "Listing Rules"). The Company received a letter from the Nasdaq in January 2019 notifying it that it was not in compliance with the minimum market value requirement set forth in Listing Rule 5550(b)(2).

  • CNW Grouplast month

    Tiara™ Featured in Presentation at 11th Annual TVT 2019

    VANCOUVER , June 17, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that its Tiara™ ("Tiara") transcatheter mitral valve replacement device was featured in a presentation at the 11th Annual Transcatheter Valve Therapy Conference ("TVT 2019"). In a presentation titled "The TIARA Program: Attributes, Challenges, and Early Clinical Data" Dr. Anson Cheung , Clinical Professor of Surgery and Director of Cardiac Transplant of British Columbia , and Principal Investigator for the Tiara Early Feasibility Study at St Paul's Hospital, Vancouver Canada , provided an update on the latest progress on the Tiara, including the challenging anatomical considerations,  patient characteristics,  procedural outcomes, and symptom improvement of patients treated with Tiara.

  • Benzingalast month

    Penny Stock Neovasc Rallies On Patent Abstract Filing

    Shares of the Canadian medical device maker Neovasc Inc (NASDAQ: NVCN) were rallying Tuesday following the circulation of a document with a patent abstract it filed with the U.S. Patent and Trademark Office. The patent abstract pertains to the methods and apparatus for loading a prosthesis onto a delivery system. This relates to the company's Tiara prosthetic valve, which replaces the mitral valve of the heart when delivered through the apex of the heart.

  • PR Newswirelast month

    Neovasc Announces Nasdaq Continuing to Monitor Minimum Market Value Deficiency Following 10 Consecutive Business Days Above US$35 Million

    VANCOUVER, June 7, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) announced today that following 10 consecutive business days with a market value of listed securities ("MVLS") of over US$35 million, the Company has been advised by staff of The Nasdaq Stock Market LLC ("Nasdaq") that the Nasdaq will exercise its discretion to continue to monitor the Company's MVLS pursuant to Nasdaq Listing Rule 5810(c)(3)(G) in connection with the Company's deficiency under the US$35 million minimum MVLS requirement. Nasdaq Listing Rule 5810(c)(3)(G) provides that Nasdaq staff may require satisfaction of the US$35 million minimum MVLS requirement for a period in excess of 10 consecutive business days, but generally no more than 20 consecutive business days, before determining that the Company has demonstrated an ability to maintain long-term compliance.

  • PR Newswirelast month

    Neovasc Inc. Reports Results of Annual General and Special Meeting of Shareholders and Provides Update on Neovasc Reducer™

    VANCOUVER, June 4, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) is pleased to announce the results of the votes on matters considered at its Annual General and Special Meeting of Shareholders held on June 4, 2019 in Vancouver, B.C. (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") re-elected board members Steven Rubin, Paul Geyer, Doug Janzen, Dr. Jane Hsiao and Alexei Marko and elected Fred Colen to serve in office until the next annual meeting or until their successors are duly elected or appointed. At the Meeting, the Shareholders also approved resolutions authorizing the Company's Board of Directors to, at their discretion, execute a common share consolidation (72.43% of votes cast in favour) and re-appointing Grant Thornton LLP, Chartered Accountants as auditors of the Company.

  • CNW Group2 months ago

    Neovasc Announces Publication of Peer-Reviewed Article in European Heart Journal Concluding Positive Cost-Effectiveness of the Neovasc Reducer™

    VANCOUVER , May 28, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the European Heart Journal, Quality of Care and Clinical Outcomes has published a peer-reviewed article indicating the cost effectiveness of the Neovasc Reducer™ ("Reducer") as an effective therapy for patients suffering from refractory angina, and its positive impact on healthcare burden.

  • Benzinga2 months ago

    A Look At Benzinga Pro's Most-Searched Tickers For May 24

    Tesla Inc  (NASDAQ: TSLA ) shares dropped 2.5 percent to $190.52. The stock rebounded above $200 on Thursday on news of a purported internal email from Musk on the company's fourth-quarter deliveries. ...

  • PR Newswire2 months ago

    New Tiara and Reducer Data Presented in Several Presentations at the EuroPCR 2019 Conference in Paris

    VANCOUVER, May 23, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that new data for its Tiara™ ("Tiara") transcatheter mitral valve replacement device and Neovasc Reducer™ ("Reducer") device for the treatment of refractory angina were presented in several presentations at the EuroPCR 2019 Conference held this week in Paris, France.